This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Carcinoma, Renal Cell
and you are
over 65
years old
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

This prospective, single arm, multi-center pilot study includes 120 mRCC patients over 65 years, no prior systemic treatment, determined to be candidates for systemic therapy by the investigator. The treatment with Sorafenib should comply with the recommendations written in the local product information. The primary endpoint is overall survival. The secondary endpoints including other effectiveness points, safety and patients characteristics. With 120 completed patients, if the observed survival rate at 12 months is 60%, the width of a 95% confidence interval will be approximately 18%.

Provided treatments

  • Drug: Sorafenib (Nexavar, BAY43-9006)
Tris trial is registered with FDA with number: NCT01728948. The sponsor of the trial is Bayer and it is looking for 60 volunteers for the current phase.
Official trial title:
Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib